Related Experiment Video

Updated: Apr 6, 2026

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

2.5K

Stomatitis Associated With Use of mTOR Inhibitors: Implications for Patients With Invasive Breast Cancer

Josephine Divers1, Joyce O'Shaughnessy1

  • 1Texas Oncology-Baylor Charles A. Sammons Cancer Center in Dallas.

Clinical Journal of Oncology Nursing
|July 25, 2015
PubMed
Abstract

Insights

Nurses can manage everolimus-induced stomatitis in advanced breast cancer patients. Steroid-based mouth rinses and other strategies improve patient outcomes and reduce treatment interruptions.

Area of Science:

  • Oncology
  • Pharmacology
  • Nursing Education

Background:

  • Everolimus, a mammalian target of rapamycin (mTOR) inhibitor, is used for advanced hormone receptor-positive, HER2-negative breast cancer resistant to endocrine therapy.
  • Stomatitis is a common dose-limiting side effect of everolimus, often leading to treatment discontinuation or dose reduction.

Purpose of the Study:

  • To educate nurses on identifying and managing stomatitis in patients with hormone receptor-positive advanced breast cancer treated with mTOR inhibitors.
  • To provide strategies for improving patient outcomes through effective stomatitis management.

Main Methods:

  • Literature review focusing on stomatitis incidence, identification, and management in cancer, specifically breast cancer.
  • Description of clinical experiences in managing stomatitis at the authors' cancer center.

Main Results:

  • Clinical evidence supports the efficacy of steroid-based mouth rinses as an adjunct treatment for stomatitis.
  • Clinical experience offers practical insights into preventive and management strategies for everolimus-induced stomatitis.

Conclusions:

  • Effective management of stomatitis is crucial for patients receiving everolimus for advanced breast cancer.
  • Implementing evidence-based and experiential strategies can improve patient adherence and outcomes.
Keywords:
mTOR inhibitorsprevention strategiessteroid mouth rinsesstomatitistolerability

More Related Videos

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module10:39

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module

Published on: June 18, 2015

13.9K
Development of a Human Preclinical Model of Osteoclastogenesis from Peripheral Blood Monocytes Co-cultured with Breast Cancer Cell Lines06:00

Development of a Human Preclinical Model of Osteoclastogenesis from Peripheral Blood Monocytes Co-cultured with Breast Cancer Cell Lines

Published on: September 13, 2017

7.7K

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.7K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
6.4K